My dad has got melasma... How long it takes to get cure
melasma treatment duration how long to cure 2025
melasma facial hyperpigmentation clinical photo

This clinical photograph displays the facial skin of a patient with melasma, specifically focusing on the lateral cheek and temple area. The image reveals numerous hyperpigmented macules and patches of varying sizes and shapes. These pigmented lesions range in color from light tan to dark brown, demonstrating a patchy, heterogeneous distribution typical of dermal or mixed melasma. The skin surface appears smooth and hydrated with a visible reflective sheen, and there are no signs of scaling, erythema, or post-inflammatory hyperpigmentation (PIH). The visual evidence represents a follow-up state after multiple treatment modalities, including Q-switched 1064 nm Nd:YAG laser sessions and adjuvant vitamin C therapy. The educational focus is on identifying clinical patterns of facial hyperpigmentation and evaluating treatment response in dermatologic practice for disorders of pigmentation.

This clinical photograph comparison shows the face of a 39-year-old female patient diagnosed with facial melasma, highlighting a before-and-after treatment progression over three months. Image (A) displays baseline hyperpigmentation characterized by confluent, brownish patches with irregular borders, symmetrically distributed across the malar regions (cheeks) and the nasal bridge. The pigmentation appears dense with a mottled texture. Image (B), taken three months after laser therapy, demonstrates a significant clinical improvement. There is a visible reduction in the size, color intensity, and overall density of the melasma patches. The skin tone appears more uniform and brightened, with less prominent follicular or pore visibility in the affected areas. This comparison illustrates the effectiveness of dermatological laser intervention for managing epidermal and dermal hyperpigmentation disorders in adult patients.

| Treatment | Visible Improvement |
|---|---|
| Topical creams (hydroquinone, tretinoin) | 8-12 weeks |
| Triple combination cream (Kligman's formula) | 8-12 weeks, often used in cycles |
| Chemical peels (glycolic, salicylic acid) | 4-8 weeks per session |
| Laser/IPL therapy | 3-6 sessions over weeks to months |
| Oral tranexamic acid | 8-12 weeks with doctor's monitoring |
| Sun protection alone | Gradual; prevents worsening |
Why tracrolimus ointment used
tacrolimus ointment melasma mechanism of action why used
| Reason | Explanation |
|---|---|
| Anti-inflammatory effect | Reduces local skin inflammation that stimulates melanocytes (pigment cells) to produce excess melanin |
| Steroid-sparing alternative | The standard Kligman's triple combination uses a corticosteroid to control inflammation - tacrolimus can replace this steroid, avoiding long-term steroid side effects (skin thinning, telangiectasia, perioral dermatitis) |
| Blocks cytokine-driven pigmentation | Cytokines like IL-1 and TNF-α stimulate melanogenesis; by blocking them, tacrolimus slows down pigment production |
| Used in combination formulas | In pilot studies, tacrolimus combined with tazarotene, azelaic acid, and zinc oxide showed effective melanin reduction by targeting multiple pathways at once |